Publicacións en colaboración con investigadores/as de Hospital de Galdakao - Usansolo (32)

2024

  1. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 10, pp. 737-741

2021

  1. Corrigendum to “Recomendaciones del Grupo Español de Trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento” [Gastroenterología y Hepatología 2020;43(10):649-658](S0210570520301606)(10.1016/j.gastrohep.2020.04.004)

    Gastroenterologia y Hepatologia

  2. Increased use of healthcare resources during the preclinical period of inflammatory bowel disease

    Digestive and Liver Disease

  3. Look at Both Sides of the Coin in Determining Risk of Complicated Crohn's Disease

    Clinical Gastroenterology and Hepatology

  4. Risk of Depression during the Natural History of Inflammatory Bowel Disease: The Phantom Menace

    Inflammatory Bowel Diseases

  5. Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies

    Gastroenterologia y Hepatologia, Vol. 44, Núm. 8, pp. 587-598

2020

  1. COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020)

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 7, pp. 408-413

  2. Early microscopic findings in preclinical inflammatory bowel disease

    Digestive and Liver Disease, Vol. 52, Núm. 12, pp. 1467-1472

  3. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 10, pp. 649-658

2019

  1. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients

    Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854

  2. Effectiveness and safety of the switch from remicade® to CT-P13 in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 13, Núm. 11, pp. 1380-1386

  3. Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: the Practicrohn study

    Expert Review of Gastroenterology and Hepatology, Vol. 13, Núm. 8, pp. 807-813

  4. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

    Therapeutic Advances in Gastroenterology, Vol. 12

  5. Granulocyte–monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis

    Scandinavian Journal of Gastroenterology, Vol. 54, Núm. 4, pp. 459-464

  6. Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicentre Study

    Journal of Crohn's and Colitis, Vol. 13, Núm. 8, pp. 996-1002

  7. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 568-578

  8. Short Disease Duration Does Not Always Indicate Early Crohn's Disease

    Clinical Gastroenterology and Hepatology

  9. The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?

    Journal of Clinical Apheresis, Vol. 34, Núm. 6, pp. 680-685